4.9App Store rating
1M+meals logged

GLP-1 research, what 2022 to 2026 found.

Weight, heart outcomes, muscle and what happens after stopping, read from the original papers.Last reviewed Nov 18, 2026

Clay still life of a bowl of cooked lentils, a boiled egg, a lemon wedge and a glass of water on a soft peach tabletop
Studies
7
People studied
39K
Trials and reviews
7
Last reviewed
Nov 18, 2026

The short answer

In trials, GLP-1 medicines lowered weight, and lowered heart events in people with heart disease. Weight returned after stopping. Lean mass was 25% to 39% of weight lost, close to the 26% seen with lifestyle programs.

What the studies cover

Evidence at a glance

  • Weight loss

    Tirzepatide 20.2%, semaglutide 13.7% over 72 weeks in one head-to-head trial

    HelpsModerate

    Studies: Jul 2025Jan 2024

  • Heart events

    6.5% with semaglutide vs 8.0% on placebo in 17,604 adults with heart disease

    Helps a littleModerate

    Study: Dec 2023

  • Weight after stopping

    About two-thirds regained in one trial; pooled regain 5.63 kg

    Linked with higher riskVery strong

    Studies: Aug 2022Dec 2025

  • Lean mass share of loss

    25% to 39% on GLP-1 medicines, near 26% with lifestyle programs

    No clear effectVery strong

    Studies: Jun 2026May 2025

Strength comes from study design and how many studies back the row. Observational studies show links, not cause.

The basics

Overview

What are GLP-1 medicines?

GLP-1 medicines such as semaglutide and tirzepatide are prescribed for obesity and diabetes. Alma does not prescribe or advise on them, and this page only summarizes published trials.

What does the research show?

In 751 adults, tirzepatide lowered weight by 20.2% and semaglutide by 13.7% over 72 weeks. Semaglutide also lowered major cardiovascular events, 6.5% versus 8.0% on placebo, in 17,604 adults with heart disease.

More questions (2)

What are the drawbacks or open questions?

Weight returned after stopping: people regained about two-thirds of lost weight within a year in one trial. Lean mass made up 25% to 39% of weight lost, and regain varied widely between trials.

What does it mean for your plate?

Eggs, Greek yogurt, tofu and lentils are everyday protein foods. The trials tested medicines, not eating plans.

2022 to 2026

The studies

Each one is dated and linked to the paper. Tap details for the people studied and the abstract line.

  • New England Journal of Medicine

    Weekly semaglutide lowered major cardiovascular events (6.5% vs 8.0% on placebo) in adults 45 and older with heart disease and no diabetes.

    Randomized trialStrong
    Show detailsHide details

    17,604 adults with heart disease and overweight, followed about 40 months

    A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001).

    On your plateVegetables, beans, whole grains, fish and olive oil stay the core of most heart-health advice.

    Read the paperPubMed

  • New England Journal of Medicine

    Tirzepatide lowered weight by 20.2% and semaglutide by 13.7% over 72 weeks in this open-label head-to-head trial.

    Randomized trialModerate
    Show detailsHide details

    751 adults with obesity, no diabetes, 72 weeks

    The least-squares mean percent change in weight at week 72 was -20.2% (95% confidence interval [CI], -21.4 to -19.1) with tirzepatide and -13.7% (95% CI, -14.9 to -12.6) with semaglutide (P<0.001).

    On your plateEggs, Greek yogurt, fish and tofu are compact protein foods.

    Read the paperPubMed

  • JAMA

    After 36 weeks on tirzepatide, people switched to placebo regained 14.0% of body weight, while those who continued lost a further 5.5%.

    Randomized trialModerate
    Show detailsHide details

    670 adults who first lost weight on tirzepatide, 36-week lead-in, then 52 weeks

    The mean percent weight change from week 36 to week 88 was -5.5% with tirzepatide vs 14.0% with placebo (difference, -19.4% [95% CI, -21.2% to -17.7%]; P < .001).

    On your plateProtein and fiber foods such as beans, eggs and vegetables are everyday building blocks for filling meals.

    Read the paperPubMed

See all 7 studies
  • Diabetes, Obesity and Metabolism

    In this exploratory extension, people regained about two-thirds of the weight lost one year after stopping semaglutide; cardiometabolic markers mostly reverted toward baseline.

    Randomized trialModerate

    327 adults, one year after stopping, 68 weeks on, then 52 weeks off

    One year after withdrawal of once-weekly subcutaneous semaglutide 2.4 mg and lifestyle intervention, participants regained two-thirds of their prior weight loss, with similar changes in cardiometabolic variables.

    On your plateThis trial tested a medicine, not food. A prescriber is the person to ask about any medicine change.

    Read the paperPubMed

  • eClinicalMedicine

    After stopping a GLP-1 medicine, people with obesity regained a pooled 5.63 kg and HbA1c rose 0.25%; results varied widely between trials.

    Meta-analysis of RCTsVery strong

    18 trials, 3,771 adults and adolescents, at least 12 weeks after stopping

    Among individuals with obesity, discontinuation of GLP-1RA resulted in significant metabolic rebound, characterized by a body weight gain of 5.63 kg (95% CI: 3.52-7.73, I2 = 99.57%, moderate) and an increase in HbA1c of 0.25% (95% CI: 0.18-0.32, I2 = 98.45%, moderate).

    On your plateMeals with fiber and protein foods are everyday choices whatever medicine plan a person follows.

    Read the paperPubMed

  • Diabetes, Obesity and Metabolism

    Lean mass was 25% to 39% of weight lost on GLP-1 medicines and 26% with lifestyle programs; with resistance training added, 17.5%.

    Meta-analysis of RCTsVery strong

    20 trials, 15,782 adults, trials of varied length

    Lean mass constituted 25%-39% of total weight lost with incretin agonists: semaglutide (35.2% [95% CI: 31.5-38.9]), tirzepatide (25.4% [22.8-28.0]) and liraglutide (26.8% [23.1-30.5]). Lifestyle interventions showed comparable proportional lean mass loss (26.2% [24.1-28.3]; p = 0.42 for comparison), while lifestyle plus resistance training demonstrated the most favourable profile (17.5% [14.2-20.8]).

    On your plateEggs, Greek yogurt, fish, tofu and lentils are everyday protein foods.

    Read the paperPubMed

  • Diabetes, Obesity and Metabolism

    About 75% of the weight lost on tirzepatide was fat and 25% was lean mass, the same split seen with placebo.

    Randomized trialModerate

    160 adults in a body scan substudy, 72 weeks

    Of the body weight lost, approximately 75% was fat mass and 25% was lean mass for both tirzepatide and placebo.

    On your plateChicken, beans, cottage cheese and salmon are easy ways to put protein on each plate.

    Read the paperPubMed

Dots rate the study design and size, from early signal to very strong.

Everyday foods

On your plate

  • EggsEggsA compact protein food
  • Greek yogurtGreek yogurtA compact protein food that fits breakfast or snacks
  • LentilsLentilsA cooked plant protein that also carries fiber

Make it yours

Research is general. Alma builds yours.

  • Meals fit to your goal and the foods you like
  • Log a meal by photo, voice or text in about 10 seconds
  • Every meal gets an Alma Score from 0 to 100
A clay cup of green tea with blueberries and walnuts

Questions

What else do people ask?

How much muscle is lost on GLP-1 medicines?

A 2026 meta-analysis of 20 trials found lean mass made up about 25% to 39% of the weight lost, close to the share seen with lifestyle programs. The share was smaller when resistance training was added.

What happens after stopping a GLP-1 medicine?

In the STEP 1 extension, people regained about two-thirds of lost weight within a year. A 2025 meta-analysis of 18 trials found an average regain of 5.63 kg in people with obesity. A prescriber is the person to ask about any change.

What does the research say about eating on these medicines?

The trials on this page tested medicines, not eating plans. The 2026 meta-analysis found a smaller lean mass share of weight lost when resistance training was added, and its authors also name adequate protein intake.

Does Alma prescribe GLP-1 medicines?

No. Alma is a nutrition app. It does not prescribe or advise on medicines, and this page only summarizes published research. Decisions about a medicine belong with a licensed clinician.

Anyone taking a GLP-1 or diabetes medicine, who is pregnant, or who has a history of an eating disorder should talk with a clinician before changing food, supplements or medicines.

Sources

Written by Alma from the papers below and last reviewed Nov 18, 2026. Each study was checked against its PubMed or journal record. This is general information, not medical advice. If you manage a health condition or take medication, check changes with your clinician. Editorial standards

  1. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes New England Journal of Medicine, Dec 2023. DOI PubMed 37952131
  2. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity New England Journal of Medicine, Jul 2025. DOI PubMed 40353578
  3. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial JAMA, Jan 2024. DOI PubMed 38078870
  4. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension Diabetes, Obesity and Metabolism, Aug 2022. DOI PubMed 35441470
  5. Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis eClinicalMedicine, Dec 2025. DOI PubMed 41399474
  6. Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials Diabetes, Obesity and Metabolism, Jun 2026. DOI PubMed 41877354
  7. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight Diabetes, Obesity and Metabolism, May 2025. DOI PubMed 39996356

Get a week built around you.

Tell Alma your goal and the foods you like. It plans the meals and scores each one.